Suharyono 1992b.

Study characteristics
Methods	Trial design: Randomized controlled trial (individually randomized) Trial dates and duration: Sept to Oct 1990
Participants	Number of participants: 140 Inclusion criteria: As for Suharyono 1992a Exclusion criteria: As for Suharyono 1992a
Interventions	Vaccine: CVD 103‐HgR live attenuated vaccine containing: 5 x 109 CFU CVD 103HgR centrifuged 5 x 1010 CFU CVD 103HgR centrifuged 5 x 109 CFU CVD 103HgR filtered 5 x 1010 CFU CVD 103HgR filtered Half of the children in each of these groups were randomized to also receive an extra half dose of buffer Placebo: 5 x 108 CFU inactivated E. coli K12 strain
Outcomes	As for Suharyono 1992a
Notes	Location: As for Suharyono 1992a Setting: Source of funding: As for Suharyono 1992a
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: 'the child was allocated to receive one of the nine treatment groups, according to a randomised sequence' Comment: Study A in the same paper used a computer to generate the sequence.
Allocation concealment (selection bias)	Low risk	Comment: Only clearly described for study A but probably done.
Blinding (performance bias and detection bias) Efficacy outcomes	Unclear risk	Not applicable as efficacy not reported
Blinding (performance bias and detection bias) Safety outcomes	Low risk	Quote: 'The clinical follow‐up as well as the administration of the vaccine was double‐blind with neither the clinical staff, the patient or their parents knowing the identity of the preparation'.
Incomplete outcome data (attrition bias) Efficacy outcomes	Unclear risk	Not applicable as efficacy not reported
Incomplete outcome data (attrition bias) Safety outcomes	Low risk	Comment: No losses to follow up are reported
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting
Other bias	Low risk	No evidence of other bias